Cargando…

Antiviral Potential of Natural Resources against Influenza Virus Infections

Influenza is a severe contagious disease caused by influenza A and B viruses. The WHO estimates that annual outbreaks lead to 3–5 million severe infections of which approximately 10% lead to the death of the patient. While vaccination is the cornerstone of prevention, antiviral drugs represent the m...

Descripción completa

Detalles Bibliográficos
Autores principales: Eichberg, Johanna, Maiworm, Elena, Oberpaul, Markus, Czudai-Matwich, Volker, Lüddecke, Tim, Vilcinskas, Andreas, Hardes, Kornelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693975/
https://www.ncbi.nlm.nih.gov/pubmed/36366550
http://dx.doi.org/10.3390/v14112452
_version_ 1784837680497950720
author Eichberg, Johanna
Maiworm, Elena
Oberpaul, Markus
Czudai-Matwich, Volker
Lüddecke, Tim
Vilcinskas, Andreas
Hardes, Kornelia
author_facet Eichberg, Johanna
Maiworm, Elena
Oberpaul, Markus
Czudai-Matwich, Volker
Lüddecke, Tim
Vilcinskas, Andreas
Hardes, Kornelia
author_sort Eichberg, Johanna
collection PubMed
description Influenza is a severe contagious disease caused by influenza A and B viruses. The WHO estimates that annual outbreaks lead to 3–5 million severe infections of which approximately 10% lead to the death of the patient. While vaccination is the cornerstone of prevention, antiviral drugs represent the most important treatment option of acute infections. Only two classes of drugs are currently approved for the treatment of influenza in numerous countries: M2 channel blockers and neuraminidase inhibitors. In some countries, additional compounds such as the recently developed cap-dependent endonuclease inhibitor baloxavir marboxil or the polymerase inhibitor favipiravir are available. However, many of these compounds suffer from poor efficacy, if not applied early after infection. Furthermore, many influenza strains have developed resistances and lost susceptibility to these compounds. As a result, there is an urgent need to develop new anti-influenza drugs against a broad spectrum of subtypes. Natural products have made an important contribution to the development of new lead structures, particularly in the field of infectious diseases. Therefore, this article aims to review the research on the identification of novel lead structures isolated from natural resources suitable to treat influenza infections.
format Online
Article
Text
id pubmed-9693975
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96939752022-11-26 Antiviral Potential of Natural Resources against Influenza Virus Infections Eichberg, Johanna Maiworm, Elena Oberpaul, Markus Czudai-Matwich, Volker Lüddecke, Tim Vilcinskas, Andreas Hardes, Kornelia Viruses Review Influenza is a severe contagious disease caused by influenza A and B viruses. The WHO estimates that annual outbreaks lead to 3–5 million severe infections of which approximately 10% lead to the death of the patient. While vaccination is the cornerstone of prevention, antiviral drugs represent the most important treatment option of acute infections. Only two classes of drugs are currently approved for the treatment of influenza in numerous countries: M2 channel blockers and neuraminidase inhibitors. In some countries, additional compounds such as the recently developed cap-dependent endonuclease inhibitor baloxavir marboxil or the polymerase inhibitor favipiravir are available. However, many of these compounds suffer from poor efficacy, if not applied early after infection. Furthermore, many influenza strains have developed resistances and lost susceptibility to these compounds. As a result, there is an urgent need to develop new anti-influenza drugs against a broad spectrum of subtypes. Natural products have made an important contribution to the development of new lead structures, particularly in the field of infectious diseases. Therefore, this article aims to review the research on the identification of novel lead structures isolated from natural resources suitable to treat influenza infections. MDPI 2022-11-05 /pmc/articles/PMC9693975/ /pubmed/36366550 http://dx.doi.org/10.3390/v14112452 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Eichberg, Johanna
Maiworm, Elena
Oberpaul, Markus
Czudai-Matwich, Volker
Lüddecke, Tim
Vilcinskas, Andreas
Hardes, Kornelia
Antiviral Potential of Natural Resources against Influenza Virus Infections
title Antiviral Potential of Natural Resources against Influenza Virus Infections
title_full Antiviral Potential of Natural Resources against Influenza Virus Infections
title_fullStr Antiviral Potential of Natural Resources against Influenza Virus Infections
title_full_unstemmed Antiviral Potential of Natural Resources against Influenza Virus Infections
title_short Antiviral Potential of Natural Resources against Influenza Virus Infections
title_sort antiviral potential of natural resources against influenza virus infections
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693975/
https://www.ncbi.nlm.nih.gov/pubmed/36366550
http://dx.doi.org/10.3390/v14112452
work_keys_str_mv AT eichbergjohanna antiviralpotentialofnaturalresourcesagainstinfluenzavirusinfections
AT maiwormelena antiviralpotentialofnaturalresourcesagainstinfluenzavirusinfections
AT oberpaulmarkus antiviralpotentialofnaturalresourcesagainstinfluenzavirusinfections
AT czudaimatwichvolker antiviralpotentialofnaturalresourcesagainstinfluenzavirusinfections
AT luddecketim antiviralpotentialofnaturalresourcesagainstinfluenzavirusinfections
AT vilcinskasandreas antiviralpotentialofnaturalresourcesagainstinfluenzavirusinfections
AT hardeskornelia antiviralpotentialofnaturalresourcesagainstinfluenzavirusinfections